A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Authors
Corrie, PBulusu, R
Wilson, C
Armstrong, G
Bond, S
Hardy, R
Lao-Sirieix, S
Parashar, D
Ahmad, A
Daniel, F
Hill, M
Wilson, Gregory
Blesing, C
Moody, A
McAdam, K
Osborne, M
Affiliation
Oncology Division, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK.Issue Date
2012-08-07
Metadata
Show full item recordAbstract
Pyridoxine is frequently used to treat capecitabine-induced hand-foot syndrome (HFS), although the evidence of benefit is lacking. We performed a randomised placebo-controlled trial to determine whether pyridoxine could avoid the need for capecitabine dose modifications and improve outcomes.Citation
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. 2012, 107 (4):585-7 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2012.318PubMed ID
22814578Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2012.318
Scopus Count
Collections
Related articles
- Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
- Authors: Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, Ryu MH, Chang HM, Lee JL, Kim TW
- Issue date: 2010 Aug 20
- Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
- Authors: Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S, Mok ZY, Koh KX, Toh HC, Koo WH, Loh M, Ng RCH, Choo SP, Soong RCT
- Issue date: 2017 Nov 1
- The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
- Authors: Ota M, Tatsumi K, Suwa H, Watanabe J, Watanabe K, Osada S, Tanaka K, Shoichi F, Ichikawa Y, Kunisaki C, Endo I
- Issue date: 2014 Jun
- Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
- Authors: Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, Tsuzuki N, Yamashita H, Toyama T, Kondo N, Iwata H
- Issue date: 2010 Oct
- A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
- Authors: Toyama T, Yoshimura A, Hayashi T, Kobayashi N, Saito K, Tsuneizumi M, Sawaki M, Hattori M, Nakada T, Yokota I, Iwata H
- Issue date: 2018 Nov